Novo Nordisk A/S (NVO)
Novo Nordisk Market Cap : 139.29B for Nov. 13, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| November 13, 2026 | 139.29B |
| November 12, 2026 | 136.01B |
| November 11, 2026 | 137.48B |
| November 10, 2026 | 136.18B |
| November 09, 2026 | 138.45B |
| November 06, 2026 | 134.87B |
| November 05, 2026 | 134.84B |
| November 04, 2026 | 141.13B |
| November 03, 2026 | 134.47B |
| November 02, 2026 | 135.34B |
| October 30, 2026 | 133.84B |
| October 29, 2026 | 130.96B |
| October 28, 2026 | 128.11B |
| October 27, 2026 | 129.39B |
| October 26, 2026 | 130.92B |
| October 23, 2026 | 130.66B |
| October 22, 2026 | 131.93B |
| October 21, 2026 | 130.69B |
| October 20, 2026 | 131.66B |
| October 19, 2026 | 128.55B |
| October 16, 2026 | 129.92B |
| October 15, 2026 | 131.23B |
| October 14, 2026 | 127.54B |
| October 13, 2026 | 127.34B |
| October 12, 2026 | 129.08B |
| Date | Value |
|---|---|
| October 09, 2026 | 129.28B |
| October 08, 2026 | 127.75B |
| October 07, 2026 | 128.01B |
| October 06, 2026 | 125.57B |
| October 05, 2026 | 125.60B |
| October 02, 2026 | 124.87B |
| October 01, 2026 | 125.14B |
| September 30, 2026 | 126.84B |
| September 29, 2026 | 128.18B |
| September 28, 2026 | 129.52B |
| September 25, 2026 | 129.82B |
| September 24, 2026 | 129.22B |
| September 23, 2026 | 127.71B |
| September 22, 2026 | 131.83B |
| September 21, 2026 | 133.17B |
| September 18, 2026 | 144.68B |
| September 17, 2026 | 144.51B |
| September 16, 2026 | 139.56B |
| September 15, 2026 | 142.30B |
| September 14, 2026 | 145.38B |
| September 11, 2026 | 144.11B |
| September 10, 2026 | 147.25B |
| September 09, 2026 | 149.09B |
| September 08, 2026 | 151.10B |
| September 04, 2026 | 155.92B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
Market Cap Benchmarks
| AstraZeneca PLC | 572.10B |
| GSK Plc | 101.13B |
| Johnson & Johnson | 687.83B |
| Eli Lilly & Co. | 1.359T |
| Merck & Co., Inc. | 364.49B |
Market Cap Related Metrics
| PE Ratio | 10.49 |
| PS Ratio | 3.561 |
| PEG Ratio | 0.6765 |
| Price to Book Value | 5.561 |
| Price to Free Cash Flow | 26.48 |
| Price | 41.63 |
| Earnings Yield | 9.54% |
| PEGY Ratio | 0.5292 |
| Operating PE Ratio | 7.365 |
| Normalized PE Ratio | 9.467 |